Showing 2521-2530 of 5771 results for "".
- Oculis Announces US Public Listing on Nasdaqhttps://modernod.com/news/oculis-announces-us-public-listing-on-nasdaq/2481444/Starting today, Oculis’ shares will trade on the Nasdaq Stock Market under the ticker symbol "OCS." The listing comes after successfully closing the business combination between European Biotech Acquisition Corp. (EBAC) and Oculis SA. The business combination was un
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-plans-to-submit-24-month-phase-3-data-to-the-fda-for-pegcetacoplan-nda-for-geographic-atrophy-ga/2481233/Apellis Pharmaceuticals provided an update on its new drug application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company plans to submit the 24-month efficacy data from the phase 3 DERB
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of
- Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findingshttps://modernod.com/news/bausch-lomb-announces-webinar-for-eye-care-professionals-on-new-areds2-study-findings/2481111/
- Johnson & Johnson Vision Announces New Data and Sustainability Activities at ESCRShttps://modernod.com/news/johnson-johnson-vision-announces-new-data-and-sustainability-activities-at-escrs/2481095/Johnson & Johnson Vision will be presenting new data and participating in a series of events at the upcoming 40th European Society of Cataract and Refractive Surgeons (ESCRS) congress September 16-20, 2022. The congress, taking place at the Milano Convention Centre in Milan, Italy, will showc
- Show Organizers Announce Reimagined Floor Plan for Vision Expo East 2023https://modernod.com/news/show-organizers-announce-reimagined-floor-plan-for-vision-expo-east-2023/2481037/The Vision Council and RX, co-organizers of Vision Expo, shared plans for a reimagined show floor layout that will debut at Vision Expo East 2023, taking place March 16–19 at the Javits Center in New York City. The new layout will feature all of Vision Expo’s Show Fl
- American Academy of Optometry and American Academy of Optometry Foundation Announces 2022 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-and-american-academy-of-optometry-foundation-announces-2022-award-recipients/2481036/
- Formosa Pharmaceuticals and AimMax Therapeutics Announce Topline Results from CPN-301 for the Treatment of Inflammation and Pain After Cataract Surgeryhttps://modernod.com/news/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-successful-topline-results-from-cpn-301-for-the-treatment-of-inflammation-and-pain-after-cataract-surgery/2480937/Formosa Pharmaceuticals and AimMax Therapeutics reported successful topline results from CPN-301, the first of two pivotal phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a corticosteroid, clobetasol propionate(0.05%), for the treatment of inflamma
- AGTC Announces Positive 3-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosahttps://modernod.com/news/agtc-announces-positive-3-month-interim-results-from-skyline-trial-of-agtc-501-for-the-treatment-of-x-linked-retinitis-pigmentosa/2480865/Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).